Search results
Results from the WOW.Com Content Network
Insulin degludec (INN/USAN) is an ultralong-acting basal insulin analogue that was developed by Novo Nordisk under the brand name Tresiba. [7] It is administered via subcutaneous injection to help control the blood sugar level of those with diabetes .
Insulin degludec/insulin aspart, sold under the brand name Ryzodeg, is a fixed-dose combination medication for the treatment of diabetes mellitus. [6] [7] [8] ...
Insulin degludec/liraglutide, sold under the brand name Xultophy, is a fixed-dose combination medication for the treatment of adults with type 2 diabetes to improve glycemic control in combination with diet and exercise. [7] [8] It contains insulin degludec and liraglutide. [7] [8] It is administered by subcutaneous injection. [7] [8]
Eli Lilly’s experimental insulin that is injected just once a week is as effective as daily insulin injections for maintaining blood sugar levels in patients with type 1 or type 2 diabetes ...
It is an ultralong-acting basal insulin analogue that is developed by Novo Nordisk. [3] It has a plasma half-life more than eight days [7] (compared to 25 hours of the previous longest-acting insulin analogue insulin degludec), making it a once-weekly basal insulin. [7] Like insulin, icodec is composed of two peptide chains linked by a ...
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee is scheduled to meet on May 24 to review Novo Nordisk A/S’s (NYSE:NVO) application seeking approval for a once-weekly insulin ...
This multi-page article lists pharmaceutical drugs alphabetically by name. Many drugs have more than one name and, therefore, the same drug may be listed more than once. Brand names and generic names are differentiated by capitalizing brand names. See also the list of the top 100 bestselling branded drugs, ranked by sales.
Like insulin, GLP-1 agonists can cause or exacerbate retinopathy, but this is believed to be caused indirectly by a rapid drop in glucose rather than a direct effect. [8] Some patients develop anti-drug antibodies , which are more common with exenatide (the antibodies were detectable in a third or more of patients) than other GLP-1 agonists and ...